Forteo ® (teriparatide [rDNA origin] injection)

20-mcg daily dose in a 2.4-mL prefilled delivery device

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

FORTEO® (teriparatide [rDNA origin] injection): Fracture Risk Reduction

Forteo reduced the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.

Detailed Information

Teriparatide reduced the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.1

Teriparatide was effective in reducing the risk for vertebral fractures regardless of age, baseline rate of bone turnover, or baseline BMD.1

Compared to placebo, teriparatide treatment significantly reduced the risk of incident vertebral fractures and nonvertebral fractures (Table 1).1

Table 1. Effect of Teriparatide on Risk of Vertebral and Nonvertebral Fractures in Postmenopausal Women With Osteoporosis1

 

Placebo

n=544

%

Teriparatide

n=541

%

Absolute Risk Reduction

%

Relative Risk Reduction

% (95% CI)

Incident vertebral fracture (≥1)

14.3

5.0a

9.3

65 (45-78)

Incident nonvertebral fracture (≥1)

5.5

2.6b

2.9

53 (12-75)

a p<.001 compared to placebo.

b p<.05 compared to placebo.

Enclosed Prescribing Information

FORTEO® (teriparatide [rDNA origin] injection), Lilly

Reference

1. Forteo [package insert]. Indianapolis IN: Eli Lilly and Company; 2019.

Glossary

BMD = bone mineral density

Date of Last Review: February 18, 2020


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 8am - 7pm ET

Or you can

Chat with us

Submit a Request

Visit Us @LillyMedical